Dr Glassner discusses her presentation at the Advances in Inflammatory Bowel Diseases virtual regional meeting August 27 on the role of leukocyte trafficking in inflammatory bowel disease.

Kerri Glassner, DO, is an assistant professor at Houston Methodist Academic Instititute-Weill Cornell in Houston, Texas.

--

TRANSCRIPT:

Kerri Glassner:
Hi. My name is Kerri Glassner and I'm a part of the Fondren Inflammatory Bowel Disease Center at Houston Methodist Hospital. I gave a talk on leukocyte trafficking at AIBD regionals. We now have multiple options for the induction and maintenance of remission in moderate to severe IBD, which is wonderful news for our patients.

Now, our job as clinicians is to help select the best therapy for each patient. The goal of my talk was to provide you with key points about S1P receptor modulators and anti integrins to aid you in the decision of when these medications may be a great option for your patients. The True North study found that Ozanimod and S1P receptor modulator is more effective than placebo for the induction and maintenance of remission in ulcerative colitis. Ozanimod is also an oral small molecule rather than a biologic, so we don't have to worry about immunogenicity like we do with the anti TNF agents.

Finally, Ozanimod is also approved for multiple sclerosis, making it an excellent option for our patients who have both ulcerative colitis and MS. Multiple studies, including Gemini I and II, have shown that Vedolizumab, an anti integrin is safe and effective for Crohn's disease and ulcerative colitis. We have long-term data that has not suggested any new safety signals, including infections or malignancy. There are very low rates of immunogenicity to Vedolizumab and immunomodulator use in combination with Vedolizumab has overall not been shown to improve outcomes. There are several studies that suggest that dosing optimization of Vedolizumab may allow recapture of a partial response. Vedolizumab has also been shown to be effective for perianal Crohn's disease, giving us another option in treatment for this specific patient group.

Finally, there are several new agents targeting different S1P receptor modulators, as well as multiple anti integrin therapies including oral options that are currently in clinical trials for Crohn's and ulcerative colitis. This includes Etrolizumab, an anti integrin that will have phase three head-to-head comparisons against infliximab and adalimumab in ulcerative colitis. Thank you very much for your attention.

--